Laboratory of America (NYSE: LH) — Perfil da empresa, notícias e dados financeiros
Laboratory Corporation of America provides comprehensive clinical laboratory services to guide patient care and drug development.
Laboratory of America
Laboratory of America is a global life sciences and healthcare services company providing comprehensive diagnostic testing and drug development solutions. The company operates central diagnostic reference and specialty laboratories that deliver routine chemistry, anatomical pathology, medical genetics, oncology, and infectious disease testing to physicians, hospitals, biopharmaceutical companies, and patients worldwide. In addition to clinical laboratory services, it provides nonclinical safety assessment, biomarker research, clinical trial central laboratory support, and real-world data analytics. Through a global network of patient service centers and digital platforms, the company facilitates direct diagnostic access, laboratory stewardship programs, and targeted precision medicine initiatives across international markets.
Resumo
Operações
Produtos e/ou serviços de Laboratory of America
- Diagnostic Reference & Specialty Laboratories: Provides routine and complex clinical laboratory testing across routine chemistry, anatomical pathology, medical genetics, oncology, neurology, and infectious diseases, supporting healthcare providers, hospitals, and patients with comprehensive diagnostic insights and testing services.
- Central Laboratory Services: Delivers global clinical trial support, including safety testing, specialty biomarker assay execution, sample management, and global logistics for pharmaceutical and biotechnology sponsors conducting phase I through phase IV clinical research studies.
- Nonclinical Development & Safety Testing: Conducts nonclinical safety assessments, toxicology evaluations, bioanalytical studies, and regulatory compliance testing for biopharmaceutical, chemical, crop protection, and novel food safety industries to advance early-stage product development.
- Patient Service Centers & Direct Testing: Operates a global network of walk-in patient service centers for specimen collection alongside direct-to-consumer digital ordering platforms, at-home collection kits, and mobile application portals for viewing and tracking diagnostic lab results.
- Hospital & Health System Solutions: Delivers specialized outreach laboratory management, reference testing services, hospital lab infrastructure support, and clinical stewardship programs to academic medical centers, regional health systems, and managed care payor organizations.
- Real-World Data & Precision Diagnostics: Offers proprietary healthcare data analytics, real-world evidence platforms, companion diagnostic development, and artificial intelligence-enhanced clinical search tools integrated with electronic health record platforms to guide targeted therapy selection.
equipe executiva do Laboratory of America
- Adam H. SchechterPresident, CEO & Chairman
- Julia A. WangCFO & Executive VP
- Brian J. CaveneyExec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer
- Jonathan C. MeltzerEVP & Chief Operations Officer
- Peter J. WilkinsonSenior VP & Chief Accounting Officer
- Akinbolade OyegunwaExecutive VP and Chief Information & Technology Officer
- Dewey SteadmanSenior Vice President of Investor Relations
- Kathryn Wright KyleExecutive VP, Chief Legal Officer and Corporate Secretary
- Amy B. SummyEVP, Chief Marketing Officer & Consumer Health Lead
- Anita Z. GrahamExecutive VP & Chief Human Resources Officer
Histórico de dividendos
Dividendos por ação pagos pela Laboratory of America, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $2.1600 |
| FY2025 | — | — | — | $2.8800 |
| FY2024 | — | — | — | $2.8800 |
| FY2023 | — | — | — | $2.6771 |
| FY2022 | — | — | — | $1.8556 |
Principais indicadores financeiros
Resultados divulgados pela Laboratory of America, em USD.
- Cap. de mercado
- 26,9 bi
- Receita (TTM)
- 14,3 bi
- P/L
- 27.4
- LPA (diluído, TTM)
- 12.1
- Dividend yield
- 0.9%
- Margem de lucro
- 7.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 14 bi | 1,5 bi | 876,5 mi | |
| 13 bi | 1,1 bi | 746 mi | |
| 12,2 bi | 725,6 mi | 418 mi | |
| 11,9 bi | 1,4 bi | 1,3 bi |